KalVista Pharmaceuticals shares latest sebetralstat findings at the American Academy of Allergy, Asthma & Immunology 2025 Annual Meeting
KalVista Pharmaceuticals announced the presentation of novel sebetralstat data related to laryngeal hereditary angioedema (HAE) attacks and adolescents with HAE at the American Academy of Allergy, Asthma & Immunology (AAAAI) / World Allergy Organization (WAO) 2025 Joint Congress taking place in San Diego, California from 28 February – 3 March 2025.
Ben Palleiko, CEO of KalVista, said: “The growing body of data from the KONFIDENT-S study consistently demonstrate that sebetralstat enabled early treatment and fast symptom relief from HAE attacks, regardless of age, attack location, or severity. This is especially critical for vulnerable populations, such as those experiencing laryngeal attacks or adolescents whose only approved options are injectable on-demand treatments. Sebetralstat, if approved, would be the first oral on-demand treatment for HAE attacks, with the potential to address some of the most significant unmet needs in HAE.”
Effectiveness of Sebetralstat for the On-demand Treatment of Laryngeal Hereditary Angioedema Attacks: Interim Analysis from KONFIDENT-S
- 32 laryngeal attacks were treated with sebetralstat (14 September 2024 cutoff)
- Median time to treatment with sebetralstat: 11.5 minutes after attack onset
- Median time to beginning of symptom relief: 1.27 hours
- 96% of those achieving beginning of symptom relief within 12 hours did so with a single dose
- No reports of difficulty swallowing film-coated tablet
On-demand Treatment of Hereditary Angioedema Attacks with Sebetralstat In Adolescents: Pooled Analysis From KONFIDENT And KONFIDENT-S
- 149 attacks were treated with sebetralstat across KONFIDENT/KONFIDENT-S (14 September 2024 cutoff)
- Median time from attack onset to treatment: 4 minutes
- Safety and efficacy consistent with adults; no serious adverse events or adverse events leading to discontinuation
(Source: KalVista)